Thursday, December 21, 2023 10:41:15 AM
I have a question and it may be infantile. I'm sure you can answer it. The offer that occurred days ago is an event where new coming investors buy x amount of shares with the option to have first sale of them? Is that right? And if a transaction of that nature occurred, then the price would remain in the same place while those shares were being allocated? Maybe what we are seeing right now and should be expected at the close of the offering?
Recent MGRX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/19/2026 08:30:58 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/15/2026 08:40:02 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/01/2026 10:31:02 AM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:25:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 08:00:33 PM
- Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc. • GlobeNewswire Inc. • 03/17/2026 08:00:00 PM
- Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds • GlobeNewswire Inc. • 03/06/2026 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2026 09:05:40 PM
- Mangoceuticals’ Patented MGX-0024 Achieves Zero Respiratory-Related Mortality in 29,000-Bird Field Trials and Demonstrates Prophylactic Benefit Against H5N1 in Controlled Government Study • GlobeNewswire Inc. • 02/23/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/19/2026 09:05:51 PM
- MangoRx Experiences Initial Success with Newly Launched $99/month All-Inclusive Injectable Testosterone Replacement Therapy (TRT) Treatment Program • GlobeNewswire Inc. • 02/19/2026 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:30:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/29/2026 05:15:19 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/23/2026 10:07:13 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 01/13/2026 10:30:48 PM
- Mangoceuticals, Inc. Announces Closing of $2.5 Million Registered Direct and Private Placements • GlobeNewswire Inc. • 12/19/2025 03:38:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 02:28:40 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/19/2025 02:13:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 12:30:48 PM
- Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy • GlobeNewswire Inc. • 12/19/2025 12:30:00 PM
- Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements Priced at the Market Under Nasdaq Rules • GlobeNewswire Inc. • 12/18/2025 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/10/2025 11:40:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2025 09:30:13 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/19/2025 04:46:17 PM
